Back to Search Start Over

Retrospective cohort study investigating synergism of air pollution and corticosteroid exposure in promoting cardiovascular and thromboembolic events in older adults.

Authors :
Josey K
Nethery R
Visaria A
Bates B
Gandhi P
Parthasarathi A
Rua M
Robinson D
Setoguchi S
Source :
BMJ open [BMJ Open] 2023 Sep 13; Vol. 13 (9), pp. e072810. Date of Electronic Publication: 2023 Sep 13.
Publication Year :
2023

Abstract

Objective: To evaluate the synergistic effects created by fine particulate matter (PM <subscript>2.5</subscript> ) and corticosteroid use on hospitalisation and mortality in older adults at high risk for cardiovascular thromboembolic events (CTEs).<br />Design and Setting: A retrospective cohort study using a US nationwide administrative healthcare claims database.<br />Participants: A 50% random sample of participants with high-risk conditions for CTE from the 2008-2016 Medicare Fee-for-Service population.<br />Exposures: Corticosteroid therapy and seasonal-average PM <subscript>2.5</subscript> .<br />Main Outcome Measures: Incidences of myocardial infarction or acute coronary syndrome (MI/ACS), ischaemic stroke or transient ischaemic attack, heart failure (HF), venous thromboembolism, atrial fibrillation and all-cause mortality. We assessed additive interactions between PM <subscript>2.5</subscript> and corticosteroids using estimates of the relative excess risk due to interaction (RERI) obtained using marginal structural models for causal inference.<br />Results: Among the 1 936 786 individuals in the high CTE risk cohort (mean age 76.8, 40.0% male, 87.4% white), the mean PM <subscript>2.5</subscript> exposure level was 8.3±2.4 µg/m <superscript>3</superscript> and 37.7% had at least one prescription for a systemic corticosteroid during follow-up. For all outcomes, we observed increases in risk associated with corticosteroid use and with increasing PM <subscript>2.5</subscript> exposure. PM <subscript>2.5</subscript> demonstrated a non-linear relationship with some outcomes. We also observed evidence of an interaction existing between corticosteroid use and PM <subscript>2.5</subscript> for some CTEs. For an increase in PM <subscript>2.5</subscript> from 8 μg/m <superscript>3</superscript> to 12 μg/m <superscript>3</superscript> (a policy-relevant change), the RERI of corticosteroid use and PM <subscript>2.5</subscript> was significant for HF (15.6%, 95% CI 4.0%, 27.3%). Increasing PM <subscript>2.5</subscript> from 5 μg/m <superscript>3</superscript> to 10 μg/m <superscript>3</superscript> yielded significant RERIs for incidences of HF (32.4; 95% CI 14.9%, 49.9%) and MI/ACSs (29.8%; 95% CI 5.5%, 54.0%).<br />Conclusion: PM <subscript>2.5</subscript> and systemic corticosteroid use were independently associated with increases in CTE hospitalisations. We also found evidence of significant additive interactions between the two exposures for HF and MI/ACSs suggesting synergy between these two exposures.<br />Competing Interests: Competing interests: None declared.<br /> (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Details

Language :
English
ISSN :
2044-6055
Volume :
13
Issue :
9
Database :
MEDLINE
Journal :
BMJ open
Publication Type :
Academic Journal
Accession number :
37709308
Full Text :
https://doi.org/10.1136/bmjopen-2023-072810